Item Infomation

Full metadata record
DC FieldValueLanguage
dc.contributor.authorIgnacio, Martin-Loeches-
dc.contributor.authorAndrew F., Shorr-
dc.contributor.authorRichard G., Wunderink-
dc.date.accessioned2023-03-22T09:08:46Z-
dc.date.available2023-03-22T09:08:46Z-
dc.date.issued2023-
dc.identifier.urihttps://link.springer.com/article/10.1186/s13613-022-01084-8-
dc.identifier.urihttps://dlib.phenikaa-uni.edu.vn/handle/PNK/7068-
dc.descriptionCC BYvi
dc.description.abstractThe pivotal ASPECT-NP trial showed ceftolozane/tazobactam was non-inferior to meropenem for the treatment of ventilated hospital-acquired/ventilator-associated bacterial pneumonia (vHABP/VABP). Here, we evaluated treatment outcomes by degree of respiratory or cardiovascular dysfunction.vi
dc.language.isoenvi
dc.publisherSpringervi
dc.subjectpivotal ASPECT-NP triavi
dc.subjectventilator-associated bacterial pneumoniavi
dc.titleOutcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trialvi
dc.typeBookvi
Appears in CollectionsOER- Y học- Điều dưỡng

Files in This Item: